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Background: The vasculature of the brain is composed of endothelial cells, pericytes and astrocytic processes. The
endothelial cells are the critical interface between the blood and the CNS parenchyma and are a critical component of
the blood-brain barrier (BBB). These cells are innately programmed to respond to a myriad of inflammatory cytokines or
other danger signals. IL-1β and TNFα are well recognised pro-inflammatory mediators, and here, we provide compelling
evidence that they regulate the function and immune response profile of human cerebral microvascular endothelial cells
(hCMVECs) differentially.
Methods: We used xCELLigence biosensor technology, which revealed global differences in the endothelial response
between IL-1β and TNFα. xCELLigence is a label-free impedance-based biosensor, which is ideal for acute or long-term
comparison of drug effects on cell behaviour. In addition, flow cytometry and multiplex cytokine arrays were used to
show differences in the inflammatory responses from the endothelial cells.
Results: Extensive cytokine-secretion profiling and cell-surface immune phenotyping confirmed that the immune
response of the hCMVEC to IL-1β was different to that of TNFα. Interestingly, of the 38 cytokines, chemokines and growth
factors measured by cytometric bead array, the endothelial cells secreted only 13. Of importance was the observation that
the majority of these cytokines were differentially regulated by either IL-1β or TNFα. Cell-surface expression of ICAM-1 and
VCAM-1 were also differentially regulated by IL-1β or TNFα, where TNFα induced a substantially higher level of expression
of both key leukocyte-adhesion molecules. A range of other cell-surface cellular and junctional adhesion molecules were
basally expressed by the hCMVEC but were unaffected by IL-1β or TNFα.
Conclusions: To our knowledge, this is the most comprehensive analysis of the immunological profile of brain
endothelial cells and the first direct evidence that human brain endothelial cells are differentially regulated by these two
key pro-inflammatory mediators.
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The vascular endothelium in the brain is the cellular inter-
face between the blood and the central nervous system.
These cells along with pericytes and vascular astrocytes
form an essential physical barrier to immune cells, bacterial
and viral infections (reviewed by [1, 2]). In addition, the
nutrient homeostasis of the CNS is governed by the vascu-
lar endothelium, which is selective to or permeable to a
range of small molecules and drugs [3]. Collectively, this is
often referred to as the blood-brain barrier (BBB). Rather
than being an impenetrable fortress, the BBB serves a
range of critical functions including maintaining the brain’s
immune privileged status (low frequency of leukocytes)
and tightly regulating the transfer of nutrients and waste
products [4, 5].
The main cellular component of the BBB is an un-
interrupted layer of microvascular endothelial cells that
are joined by tight-junctions (reviewed by [6]). These
cells are highly polarised, with their basolateral aspect
juxtaposed to a continuous protein-containing base-
ment membrane (basal lamina). The presence of tight-
junction complexes (e.g. claudin-5, occludin, ZO-1 (see
[7]) seals adjacent endothelial cells and restricts para-
cellular transfer of large molecules and cells [6]. The ap-
ical aspect of the vascular endothelium is in direct
contact with the blood and is therefore exposed to a
range of insults including infections and systemic in-
flammatory responses.
It has become clear that the BBB is affected or chan-
ged in a wide variety of neurological diseases (e.g. mul-
tiple sclerosis [8, 9] and HIV infection [10, 11]), and in
turn may modulate the disease process or clinical out-
come [10, 12–14]. Although endothelial cells are not
regarded as classical immune cells, extensive literature
demonstrates that endothelial cells are inextricably in-
volved in the inflammatory responses in many tissues.
This is most likely very true in the human brain;
however, most of what we believe about human brain
endothelial (BBB) function has been inferred from
observations using non-human or non-CNS-derived
endothelial cells. This includes endothelial cells from
other species [15–17] or from other tissues, such as
the umbilical vein [18]. Understandably, the number
of studies that have actually used human brain endo-
thelial cells (either primary or immortalised) repre-
sents a minor proportion of the literature.
Inflammatory cytokines regulate the function of brain
microvascular endothelial cells leading to changes in
endothelial activation [19], inflammatory phenotype [19]
and extravasation of immune cells [19–21]. Clinically,
this likely contributes to the severity of disease where BBB
dysfunction is evident. However, the temporal profile of
these changes has not been studied in detail using human
endothelial cells from the brain (or of brain origin). Herewe compare the temporal response profiles of brain endo-
thelial cells to several major pro-inflammatory regulators
(IL-1β and TNFα) and reveal that the nature of the in-
flammatory response differs substantially. Initially, we
used xCELLigence biosensor technology, which revealed
that the global temporal response of the brain endothelial
cells to IL-1β and TNFα was different. This observation
was corroborated where expression or secretion of a num-
ber of key pro-inflammatory mediators were differentially
regulated by IL-1β and TNFα. Using an extensive cytokine
cytometric bead array (CBA) panel and flow-cytometry
panel, we also advance our understanding of which cyto-
kines, chemokines and adhesion molecules are expressed
by brain endothelial cells. IL-1β or TNFα also induced
changes in endothelial barrier strength measured as trans-
endothelial electrical resistance (TEER) using electric cell
substrate impedance-sensing (ECIS) technology. We ob-
served complex differences in the changes in TEER in-
duced by IL-1β and TNFα, where there were differences
in the magnitude of the response and temporal nature of
the response.Methods
Cell culture of hCMVECs
The human cerebral microvascular endothelial cell
(hCMVEC) line was purchased from ABMGood (USA
see http://www.abmgood.com). Cells were maintained in
growth media containing M199 media (Gibco) supple-
mented with 10 % FBS, 1 μg/mL hydrocortisone (Sigma),
3 μg/mL human FGF (Peprotech), 10 μg/mL human
EGF (Peprotech), 10 μg/mL heparin (Sigma), 2 mM Glu-
tamax (Gibco) and 80 μM butyryl cAMP (Sigma) re-
ferred to as M199 10 % growth media. The hCMVECs
experiments were typically conducted using low-serum
plating media containing M199 media, 2 % FBS, 110 nM
hydrocortisone, 1 μM insulin and 80 μM butyryl cAMP
(M199 2 % plating media).xCELLigence experiments
The xCELLigence real-time cell analyser (RTCA) mea-
sures cellular adhesion in real-time using custom E-
plates, which are coated with high-density gold arrays
for measuring electrical impedance (ACEA Biosciences,
USA) [22, 23]. The xCELLigence biosensor measures
cellular adhesion, which is converted to Cell Index (ar-
bitrary units) by the xCELLigence software (version
1.2.1). Cells were seeded into E96 well plates at 54,000
cells per well in M199 2 % plating media and allowed
to recover until the cells have attained a stable cell
index. This was typically 24 h after seeding. Cytokine
treatments are detailed in the corresponding figure
legends.
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junction proteins
For confocal imaging, the cells were grown to conflu-
ence on collagen-coated 8-chamber glass slides (BD
Biosciences. Cat, no: 354108). Cells were fixed for im-
munocytochemical staining using 4 % PFA at room
temperature for 10 min. Excess PFA was removed
with several washes using PBS.
Primary antibody against VE-cadherin/CD144 (Santa
Cruz Biotechnology Inc, sc-6458) was prepared in PBS
containing 1 % donkey serum and used at 1:200 dilution.
Primary antibody to zonula occludin-1 (ZO-1; Invitrogen,
339100) was prepared in PBS containing 1 % goat serum
and used at 1:500 dilution. Primary antibodies were incu-
bated at 4 °C overnight. Unbound antibodies were re-
moved by washing in PBS containing 0.2 % triton-X100
(PBST). Fluorophore conjugated secondary detection was
used using the species-specific anti-IgG Alexafluor 488
antibodies from Life Technologies (A-21206 and A11055).
These secondaries were used at 1:400 and incubated with
cells for 2 h at ambient. Again, unbound antibodies were
removed with gentle agitation with PBST washes. Nuclei
were counter stained using Hoescht (1:500 dilution in
PBST), and cells were mounted using AF1 mountant.
Confocal imaging was conducted using an Olympus
FV100 microscope. Images were merged using ImageJ
software.
Stimulation of hCMVEC for cytokines production
The hCMVEC cultures were seeded into 24-well plates
coated with 1 μg/cm2 collagen I (Gibco) at the density of
80,000 cells per well. Cells were grown to confluence in
M199 10 % growth media. On the day of stimulation,
the growth media was changed to M199 2 % plating
media. In the first series of experiments, the stimulatory
cytokines IL-1β and TNFα were each added to corre-
sponding wells to the final concentration of 5 ng/mL.
Control group received media only. 100 μl of condi-
tioned media was collected at 4, 24 and 72 h post-
treatment. In the second series of experiments, the
cytokines were added across a range of concentrations
(50 ng/mL to 50 pg/mL) for 24 h. The collected media
were centrifuged at 400×g for 5 min at 4 °C to remove
cellular debris. 80 μl of the clarified media was recovered
and stored in several single-use aliquots for cytokine
profiling. Media samples were stored at −20 °C.
Cytokine measurements using cytometric bead array
(CBA)
Soluble cytokines in the hCMVEC-conditioned media
were measured simultaneously using multiplexed bead-
based immunoassays, Cytometric Bead Array (CBA, BD
Biosciences). The assay was conducted using 25 μl of
sample and using a 10-point standard curve (rangingfrom 0 to 5000 pg/mL) was included for each cytokine
measured (see Table 1 for list of cytokines). The samples
were analysed using a BD Accuri C6 flow cytometer
(BD Bioscience). FCAP Array software (BD version 3.1)
was used to create the standard curves for each cyto-
kine and convert the fluorescent MFI values into cyto-
kine concentrations.Cell-surface flow-cytometry analysis of hCMVEC
The hCMVEC cultures were seeded into T75 mainten-
ance flasks and were grown to confluence in M199 10 %
growth media. On the day of stimulation, the media was
changed to M199 2 % plating media with 5 ng/mL IL-
1β, 5 ng/ml TNFα or no stimulatory cytokine added for
control group. After the designated treatment period
(see figure legends) the endothelial cells were carefully
harvested with EDTA-based Versene (Gibco). The use of
trypsin was avoided as it cleaves many of the cell-surface
epitopes. Cell suspensions were adjusted to the concen-
tration of 1 × 106 cells/ml with cold FACS buffer (PBS
and 1 % FBS) in 100 μl per tube. Fluorochrome conju-
gated antibodies (see Table 2 for list of antibodies) were
added to the cells at previously optimised dilutions and
were incubated on ice for 10 min. Cells were washed
twice with 1 ml of cold FACS buffer and were centri-
fuged at 400×g for 10 min. The supernatant was dis-
carded, and cells were re-suspended in approximately
100 μl of FACS buffer. Flow cytometry was conducted
using an Accuri C6 flow cytometer (BD Bioscience)
calibrated with appropriate compensation controls.
Each staining combination was incubated with 7AAD
for live-dead cell determination. 7AAD-positive cells
were ascribed to the dead gate (P2) and excluded
from further analysis. 7AAD-negative cells represent
the viable population and were ascribed as the live-
gate (P1) (see Additional file 1: Figure S1 for further
details). The specific staining of the flow antibodies
(detailed in Table 1) was measured for the live-gate
P1 only. The gating strategy for the flow-cytometry
experiments is shown in Additional file 1: Figure S1.Measurement of TEER using ECIS technology
ECIS 96W20idf plates were coated with 10-mM L-
cysteine to clean and modify the electrode surface so as
to provide highly reproducible electrode capacitance.
This was followed by coating the wells with 1 μg/cm2
collagen I. Then 50 μl of media was added to each well,
and well stabilisation was carried out on the ECIS ZΘ to
clean the electrodes prior to plating of cells. The
hCMVEC cells were seeded at 20,000 cells/well and cul-
tured for 48 h prior to treatment with cytokines as de-
tailed in the corresponding figure legends. Multi
frequency/time data was collected. Data were plotted at
Table 2 Details of the cell-surface adhesion molecules
investigated in this study
Stain Fluorochrome conjugate Manufacturer Catalogue number
CD102 PE Biolegend 354503
CD105 Alexa Fluor 488 Biolegend 323209
CD106 PE Biolegend 305806
CD138 APC Biolegend 352307
CD141 APC Biolegend 344106
CD144 PE Biolegend 348506
CD146 Alexa Fluor 647 Biolegend 342005
CD147 Alexa Fluor 648 Biolegend 306209
CD150 PE Biolegend 306307
CD304 PE Biolegend 354503
CD31 Alexa Fluor 488 Biolegend 303110
CD321 FITC Biolegend 353503
CD325 PE Biolegend 350805
CD34 APC Biolegend 343608
CD44 FITC Biolegend 338803
CD49d APC Biolegend 304308
CD50 APC Biolegend 330011
CD54 FITC Biolegend 353108
CD62E APC Biolegend 336011
CD62L APC Biolegend 304809
CD62P APC Biolegend 304910
7AAD BD Pharmingen 51-68981E
The table contains the marker CD name, fluorophore conjugate, manufacturer
and catalogue number
Table 1 Details of the cytokines measured in this study and
whether they were secreted by the hCMVEC cultures




Human Basic FGF Flex Set 558327 Yes
Human CD106 (VCAM-1) Flex Set 560427 Yes
Human CD54 (ICAM-1) Flex Set 560269 Yes
Human CD62E (E-Selectin) Flex Set 560419 No
Human CD62P (P-Selectin) Flex Set 560426 No
Human Soluble CD121a (IL-1 RI) Flex Set 560276 No
Human CD121b (IL-1 RII) Flex Set 560281 No
Human Eotaxin Flex Set 558329 No
Human CD178 (Fas Ligand) Flex Set 558330 No
Human Fractalkine Flex Set 560265 No
Human Granzyme B Flex Set 560304 No
Human GCSF Flex Set 558326 Yes
Human GMCSF 558335 Yes
Human IFN-γ Flex Set 558269 No
Human IL-1β Flex Set 558279 No
Human IL-2 Flex Set 558270 No
Human IL-4 Flex Set 558272 No
Human IL-6 Flex Set 558276 Yes
Human IL-7 Flex Set 558334 No
Human IL-8 Flex Set 558277 Yes
Human IL-9 Flex Set 558333 No
Human IL-10 Flex Set 558274 No
Human IL-13 Flex Set 558450 No
Human IL-17A Flex Set 560383 No
Human IL-17 F Flex Set 562151 No
Human IL-12/IL-23p40 Flex Set 560154 No
Human IL-21 Flex Set 560358 No
Human I-TAC Flex Set 560364 No
Human IP-10 Flex Set 558280 Yes
Human MCP-1 Flex Set 558287 Yes
Human MIG Flex Set 558286 No
Human MIP-1α Flex Set 558325 No
Human MIP-1β Flex Set 558288 No
Human RANTES Flex Set 558324 Yes
Human Soluble TNFRI Flex Set 560156 Yes
Human Soluble TNFRII Flex Set 560155 Yes
Human TNFα Flex Set 558273 No
Human VEGF Flex Set 558336 Yes
This panel comprises a list of chemokines, cytokines, soluble receptors and
soluble adhesion molecules. The right-hand column summarises those
cytokines that were secreted by the hCMVECs
aUnder the conditions tested
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rier formation and resistance [24].
Results
Analysis of hCMVEC response profile using xCELLigence
biosensor technology
The real-time xCELLigence biosensor was used to ascer-
tain the temporal response profile of the hCMVECs to
IL-1β and TNFα (Fig. 1). The biosensor measures the
net adhesion of living cells and is therefore ideal to
reveal (a) if the cells respond and (b) when the cells re-
spond to cytokine treatment. Figure 1a shows the long-
term changes in endothelial adhesion induced by IL-1β
and TNFα (both 5 ng/mL). Importantly, the profile sug-
gests that the endothelial response to IL-1β and TNFα is
not the same. IL-1β induces a sustained increase in
endothelial adhesion (green curve) beginning approxi-
mately 24 h after activation, whereas with TNFα, the net
endothelial adhesion is reduced for a period of ~100 fol-
lowing TNFα addition. Figure 1b focuses on the initial
24-h period after activation which shows when the cy-
tokines were added (blue arrow) and that there is only
a small change in net endothelial adhesion during this
Fig. 1 Analysis of pro-inflammatory IL-1β and TNFα activation of brain endothelial hCMVECs on cellular adhesion measured using xCELLigence Biosensor
technology. a The net endothelial adhesion (cell index) was measured using xCELLigence across a 210-h period. Endothelial cells were treated with IL-1β
(5 ng/mL; green curve) and TNFα (5 ng/mL; blue curve) 24 h after seeding. Cytokine addition is indicated by the blue arrow, whereas the red arrows
highlight the time points when conditioned media was collected (from parallel plates). The control (vehicle cells) is indicated by the red curve. b The
curves represent the mean of four individual well ± SD of a representative experiment
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In addition to the marked difference in net adhesion
between the cytokine treatments, the long-term tem-
poral profile indicates that neither treatment induces
cytotoxicity. This is in contrast to the previous observa-
tion where we have observed IL-1β- and TNFα-induced
compromise of astrocytes using xCELLigence technology
[23]. Overall, the changes in endothelial adhesion inducedby IL-1β are very different to the response to TNFα. This
provides evidence that the endothelial response to these
two key pro-inflammatory regulators is different.
Characterisation of cytokine and chemokine secretion
under basal and activated conditions
Multiplex cytokine analysis provides a powerful tool to
assess complex secretory profiles of human immune
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secretory output of the hCMVECs and measure any
changes following treatment with TNFα and IL-1β over
a time course of 3 days. This period is highlighted by the
red arrows in Fig. 1a.
In total, we measured the concentration of 38 different
secreted cytokines, chemokines, growth factors and liber-
ated soluble receptors in endothelial-conditioned media
(see Table 1 for complete list of factors). The media were
collected from brain endothelial cells maintained under
basal (no activation) conditions or following activation
with TNFα, IL-1β (Fig. 2) or PMA (see Additional file 2:
Figure S2) across a time course of 72 h. In total, 13 of the
38 factors (see Table 1) were detected in the endothelial-
conditioned media at above 1 pg /mL (lower limit of sen-
sitivity). These were soluble ICAM-1 (sICAM-1/sCD54),
sVCAM-1(sCD106), IL-6, IL-8 (CXCL8), MCP-1 (CCL2),
RANTES (CCL5), IP-10 (CXCL10), VEGF, bFGF, GCSF,
GMCSF, sTNFRI and sTNFRII. The concentration of most
of these under basal conditions was low or undetectable
(<1 pg/mL). This profile is consistent with the endothelial
cells having a non-activated/non-inflamed phenotype
under basal culture conditions. The secretion of each of
the 13 cytokines was greatly increased following in-
flammatory stimulation with TNFα or IL-1β (5 ng/mL).
Interestingly, specific factors were preferentially induced
by IL-1β (red curves), which included sICAM-1, IL-6,
sTNFRI, sTNFRII, GCSF, GMCSF and the chemokine IP-
10. In contrast, RANTES and IL-8 were preferentially
induced by TNFα. The endothelial cells were clearly re-
sponsive to both TNFα and IL-1β; however, the secretory
immune response to each was considerably different.
Interestingly, we measured the presence of the soluble
versions of ICAM-1, VCAM-1 and the receptors for
TNFα and IL-1β. As expected, soluble ICAM-1 and
VCAM-1 were undetectable in the endothelial-
conditioned media during basal culture conditions. How-
ever, both were induced and liberated following IL-1β
treatment, which resulted in a greater concentration of
soluble adhesion molecules than TNFα. Soluble TNF re-
ceptors (sTNFRI and sTNFRII) were also detected in the
endothelial-conditioned media; however, to our surprise,
the concentration of both sTNFRI and sTNFRII was in-
creased to a greater extent by IL-1β than by TNFα treat-
ment. In contrast, we did not detect the soluble forms of
the IL-1 receptor (sIL-1R1 and sIL-1R2) under any
conditions.
The phorbol ester PMA, was also used to potentially ac-
tivate a wider signaling network than that induced by
TNFα or IL-1β. PMA increased secretion of most of those
regulated by TNFα and IL-1β. The amount secreted was
generally lower in comparison to the cytokine-induced re-
sponses. That said, this clearly shows that activation of the
PKC-signalling network results in a pro-inflammatoryresponse in brain endothelial cells. There were, however,
no additional cytokines present in our panel of 38 (see
Table 1) specifically regulated by PMA.
It is worth noting that under these conditions, the
hCMVEC did not secrete the MIP1α or MIP1β, which
are potent pro-inflammatory chemokines nor did we de-
tect secretion of the anti-inflammatory cytokines IL-4 or
IL-10 from the endothelial cells under any conditions.
The temporal profile of secretion, although expensive to
conduct, reveals that IL-6 and GCSF levels at 72 h post
IL-1β activation are lower than the levels observed earl-
ier at 24 h. This is an interesting observation which sug-
gests that the endothelial cells have the capacity to
assimilate or degrade some of the cytokines they secrete.
This is also an important observation in terms of future
experiments, as the timing of media collection has to be
carefully considered in this regard to maximise sensitiv-
ity of the response, but avoiding this later period, where
additional mechanism are at play.
As the data in Fig. 2 had highlighted pronounced differ-
ences in responsiveness to TNFα and IL1β, the cytokine-
secretion study was extended to include a wider range of
concentrations for TNFα and IL1β (50 pg/mL to 50 ng/
mL; Fig. 3). Panels of cytokines were selected that were ele-
vated at 24 h for this comparison. It is evident from Fig. 3
that IL-1β is considerably more potent than TNFα in
terms of inducing secretion/release of sICAM, sVCAM,
MCP-1, GCSF and GMCSF, whereas TNFα is the more
potent inducer of the chemokine IL-8. In these data and
also in the profiling conducted in Fig. 2, we would argue
that there is only a minimal effect of TNFα on the induc-
tion of GCSF and GMCSF, in comparison to the effect of
IL-1β. This further supports the observation that TNFα
and IL1β are causing differential inflammatory responses
in the hCMVECs.Cell-surface immunophenotyping of human brain
microvascular endothelial cells
The CBA cytokine profile strongly suggested that the
endothelial response following IL-1β activation created a
different inflammatory milieu in comparison to TNFα
(see Fig. 2). It was notable that IL-1β induced the liber-
ation of more soluble ICAM-1 and VCAM-1 in com-
parison to TNFα. We therefore hypothesised that these
differences would also be reflected in the cell-surface ex-
pression level of these and other cell-adhesion molecules
(CAMs). We therefore undertook an extensive analysis
of the cell-surface immunological phenotype of the
hCMVEC cells. This comprehensive analysis included
leukocyte endothelial CAMs (see Fig. 4), adherens-
junction molecules (see Fig. 4), endothelial-matrix adhe-
sion molecules and various others (see Figs. 5 and 6 and
Additional file 3: Figure S3).
Fig. 2 (See legend on next page.)
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Fig. 2 Characterisation of the cytokine-secretion profiles of hCMVEC cultures following activation by IL-1β and TNFα. The concentration of
each secreted cytokine/chemokine was measured in conditioned media using multiplex CBA. Shown are the temporal secretion profiles
(4 to 72 h) of the 13 cytokines detected out of a larger screening panel of 38 factors (see Table 1 for full panel of cytokines). Most were
negligible or undetectable under basal conditions with secretion increasing following treatment with either IL-1β (5 ng/mL) or TNFα
(5 ng/mL) treatment. Data show the mean ± SEM (n = 3)
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these brain microvascular endothelial cells basally express
a range of adhesion molecules commonly expressed by
endothelial cells from a variety of tissues (including CD31,
CD34, CD138, CD141, CD144 and CD146). It should be
noted that very few of these markers are truly endothelial-
specific, which includes the commonly used CD31 and
CD34 molecules (also expressed by some leukocytes). In
addition, we also investigated expression and localisation
of VE-cadherin and ZO-1 in the endothelial cells using
immunocytochemistry (see Additional file 4: Figure S4).
This confirmed the high level of expression of these two
proteins as expected of brain-derived endothelial cells,
which have critical roles in controlling endothelial barrier
integrity. Of the entire panel of CAMs investigated in this
study, it was E-selectin (CD62E), ICAM-1 (CD54) and
VCAM-1 (CD106) that were consistently affected by
TNFα and IL-1β. Importantly, basal expression of these
was very low, which is consistent with a non-activated sta-
tus. All of the selectin species were measured. However,
only CD62E was induced by activation. Basal levels of P-
selectin were very low, and L-selectin (as expected) was
not expressed. Induction of CD62E was observed approxi-
mately 2–4 h after cytokine activation (see Fig. 3). Both
ICAM-1 and VCAM-1 expression were substantially
increased following activation by TNFα and IL-1β.
Such activation-induced surface expression of these
key leukocyte-attachment molecules is fully consistent
with their role in leukocyte recruitment across the
BBB. The data shown in Figs. 4 and 5 (except for the
selectins), and Additional file 3: Figure S3 shows the
expression of the cell-surface adhesion molecules 24
h after treatment. This was also conducted 72 h after
treatment (data not shown), and only ICAM-1 and
VCAM-1 showed substantial changes (summarized in
Table 3).
There was a pronounced “bimodal” change in VCAM-1
expression following 24-h IL-1β treatment, but not as evi-
dent with TNFα (Fig. 4). It is possible that the left peak
(lower expression) is related to the sVCAM-1 liberation in
a population of cells as measured during the cytokine pro-
filing. It was therefore decided to conduct a longer time
course for these key leukocyte-adhesion molecules to as-
certain their profile more fully. Figure 6 reveals the tem-
poral profile of (a) ICAM-1 and (b) VCAM-1 following
cytokine activation of the hCMVECs over a 144-h time
course. Of particular interest is that TNFα induces amarkedly higher level of both ICAM-1 and VCAM-1 ex-
pression in comparison to IL-1β. This time course reveals
that both ICAM-1 and VCAM-1 expression occurs
quickly and, in the case of ICAM-1, is sustained at high
levels for a number of days. In contrast, VCAM-1 expres-
sion is shorter lived and peaks around 24 h (highlighted
by the red line). The temporal breakdown (right-hand
plots) reveals that the increased VCAM-1 expression is bi-
modal for both IL-1β and TNFα treatments (Fig. 6).
Finally, we investigated the influence of these cyto-
kines and inflammatory conditions on endothelial bar-
rier function (Figs. 7 and 8 and Additional file 5:
Figure S5). Barrier function was measured using the
electric cell-substrate impedance-sensing (ECIS) ZΘ
(Z-theta) instrument system from Applied Biophysics
Inc (USA) [24] (see http://www.biophysics.com/barrier
function.php). This system measures barrier function (as
barrier resistance, ohms) in real-time and in a continuous
autonomous manner. Each cytokine was tested from 5 pg/
mL to 50 ng/mL, and endothelial TEER was monitored
for more than 160 h. Basal TEER (normalised to 1.0) was
relatively stable across this period and remained within 10
% of the TEER observed at the time of cytokine addition.
Both TNFα and IL1β induced changes in TEER, but the
effects were not identical. There was no net effect of
TNFα at concentrations below 50 pg/mL, whereas at 500
pg/mL and above, there was a progressive and sustained
increase in endothelial TEER. This increase in TEER was
maximal at 5 ng/mL TNFα (Fig. 8 and Additional file 5:
Figure S5).
The response to IL-1β was rather different, with the
maximal increase in TEER observed with 500 pg/mL,
and this relative increase in TEER was not as large as
that seen with TNFα. Interestingly, at 5- and 50-ng/mL
IL1β, there was a pronounced delay in the increase in
TEER of approximately 20 h, which was not observed
following TNFα treatment. These responses have been
plotted against each other for direct comparison in Fig. 8
(see also Additional file 5: Figure S5). This reveals that
the response profiles are quite different from each other,
except at 500 pg/mL (Fig. 8).
Discussion
To our knowledge this study represents the most
comprehensive simultaneous analysis of cell-surface
adhesion molecules and cytokine secretion following
pro-inflammatory cytokine activation of human brain
Fig. 3 IL-1β and TNFα differentially regulate endothelial cytokine secretion. IL-1β and TNFα were added to the endothelial cultures across
a concentration range of 50 pg/mL to 50 ng/mL, and secretions were measured by CBA after 24 h. The TNFα responses are shown in
blue whereas the IL-1β responses are in red. Data show the mean ± SEM (n = 3)
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Fig. 4 Analysis of IL-1β and TNFα regulation of key adhesion molecules involved in leukocyte adhesion. a The flow plots show the cell-surface
expression levels of adhesion molecules 24 h after cytokine treatment (5 ng/mL). Of this panel, IL-1β and TNFα treatments appear to substantially
increase CD54 (ICAM-1) and CD106 (VCAM-1) expression only. Note also the bimodal distribution for CD106 following IL-1β activation. The black
line denotes the autofluorescence of the cells. The blue curve represents the basal level of expression, whereas the red curve is the expression level
following cytokine treatment. b Time course of selectin (CD62E, P and L) expression following cytokine activation of the hCMVECs. These data are
from a single experiment, which is representative of at least three independent experiments
Fig. 5 Analysis of IL-1β and TNFα regulation of adhesion molecules involved in basolateral matrix interactions. The flow plots show the cell-surface
expression levels of adhesion molecules 24 h after cytokine treatment (5 ng/mL), with the specific adhesion molecule denoted in the top of the panel.
The black line denotes the autofluorescence of the cells. The blue curve represents the basal level of expression, whereas the red curve is the expression
level following cytokine treatment. These data are from a single experiment, which is representative of at least three independent experiments.
Additional adhesion molecules were also investigated, and these are shown in Additional file 3: Figure S3
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Fig. 6 (See legend on next page.)
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Fig. 6 Time course of ICAM-1 and VCAM expression following IL-1β and TNFα activation reveals a time- and cytokine-dependent profile
of expression. Cell-surface expression of (a) CD54 (ICAM-1) and (b) CD106 (VCAM-1) over a 6-day period under basal condition, following
endothelial activation with IL-1β (5 ng/mL) or TNFα (5 ng/mL). Expression levels are represented as MFI (mean fluorescent intensity). The
right-hand panels show the individual flow plots to highlight the bimodal expression profile present for VCAM-1. Data are representative
of three independent experiments
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to ascertain the consequence of inflammatory activation
on a broad range of immune mediators involved in BBB
neuroinflammation, leukocyte communication and recruit-
ment. The rationale was to advance our understanding ofTable 3 Expression of cell-surface adhesion molecules by brain end
Molecules Other names Supporting literature
CD102 ICAM2 Flow-cytometry analy
CD105 Endoglin Flow cytometry using
CD106 VCAM1 RT-PCR using BMVEC
CD138 Syndecan 1 Rat brain and rat bra
CD141 Thrombomodulin IHC using human bra
Regional distribution
CD144 VE-cadherin ICC using hCMEC/D3
IHC using human bra
CD146 MCAM; S-endo-1; MUC-18 Flow cytometry using
CD147 BSG
CD150 SLAMF1
CD304 Neuropilin-1 Functional assay usin
CD31 PECAM1 Flow cytometry using
Flow cytometry and
Flow cytometry and
CD321 JAM1 ICC using hCMEC/D3
IHC on human brain
CD325 Neural cadherin (NCAD)
CD34 HPCA-1 Flow cytometry using
CD44 H-CAM, Pgp-1 Flow cytometry using
CD49d Alpha 4 integrin THBMEC [39]
CD50 ICAM3 Expressed by leukocy
cells in human brain
CD54 ICAM1 Flow cytometry using
CD62E E-selectin ELISA detection using
CD62L L-selectin Not expressed
CD62P P-selectin IHC using human bra
IHC using human inf
hCMEC/D3 are immortalised human brain endothelial cell lines from adult females
cells from foetal brain tissue. THBMEC are immortalised adult transfected human br
cerebromicrovascular endothelial cells. HBMVE are primary human brain microvascu
(primary cells)
The better known generic names for each adhesion molecule are detailed alongsid
molecule in endothelial cells or in brain tissue. The final column summarises wheth
ICC immunocytochemistry, IHC immunohistochemistrythe repertoire of adhesion molecules, cytokines and che-
mokines expressed by brain endothelial cells and how these
change in a temporal manner following activation by key
inflammatory triggers (i.e. TNFα and IL-1β). Specific ex-
pression profiles for human brain endothelial cells isothelial cells
Expressed by the hCMVECs
sis using hCMEC/D3 cells [34] Yes
BMVEC [35] Yes
[35] Yes; highly inducible
in-derived endothelial cells [36] Yes
in tissue (not expressed) [37] Yes
in human brain [38]





g hCMEC/D3, and IHC-rat brain [41] Yes
hCMEC/D3 [34] Yes
RT-PCR using BMVEC [35]
ICC using HBMEC [42]






tes but not detected on endothelial
by IHC [43]
Yes; low
hCMEC/D3 [34] Yes; highly inducible
HCEC [44] Yes; highly inducible
No
in [45]; Yes; very low
arcted brain [46]
with epilepsy (not commercially available). BMVEC are human brain endothelial
ain microvascular endothelial cells. HCEC are primary adult human
lar endothelia. HBMEC are human brain-derived microvascular endothelial cell
e the literature demonstrating expression or function of the given adhesion
er the adhesion molecule was expressed by the hCMVECs used in this study
Fig. 7 TNFα and IL-1β treatment causes acute reduction in the endothelial barrier resistance. ECIS-Ztheta technology was used to measure the
barrier tightness, represented as barrier resistance. The arrow represents the time of cytokine addition, and the colour-coded key details the
respective treatments. The TNFα responses are shown in the upper graph with the IL-1β responses shown in the lower graph. Each curve represents
the mean of 4–6 wells
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cells derived from other tissues (e.g. HMEC-1 skin endo-
thelial cells).The brain endothelial cells used in this study express
all of the prototypic adhesion molecules expected of
endothelial cells; including CD31 (PECAM), CD34,
Fig. 8 Following the acute reduction in barrier resistance, TNFα and IL-1β mediate a progressive and sustained strengthening of the
endothelial barrier. The longer temporal profile measured by ECIS reveals that, following the initial small suppression of barrier resistance,
there is a pronounced increase in barrier resistance from both IL-1β and TNFα, which occurs in a time- and concentration-dependent
manner. Each curve represents the mean of 4–6 wells
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associated protein ZO-1. In addition, the hCMVECs
have very low levels of CD62E, ICAM-1 and VCAM-1
under basal non-inflamed conditions. This is consistent
with the phenotype of brain endothelial cells in vivo [31]
and confirms that our in vitro culture conditions maintain
the cells in a non-activated state. This is extremely import-
ant for being able to induce inflammation. As anticipated,
both IL-1β and TNFα increased cell-surface expression of
these key leukocyte-adhesion molecules; however, thepotency of the response and temporal nature was different
for induction of ICAM-1 and VCAM-1. Both were up-
regulated to a greater extent and for longer by IL-1β. Ele-
vated expression levels of CD62E, ICAM-1 and VCAM-1
are reliable indicators that endothelial cells have been acti-
vated in some manner. However, the temporal window of
their expression is very specific. Most of the other adhe-
sion molecules appeared unaffected by activation with IL-
1β or TNFα. However, it is worthy to note that this
conclusion is drawn from flow-cytometry analysis. As
O’Carroll et al. Journal of Neuroinflammation  (2015) 12:131 Page 16 of 18such, it is possible that compartmentalised localisation
may change, which could then affect the function of the
adhesion molecule.
Brain endothelial cells are the cellular interface between
the blood and CNS tissue and like most cells with innate
immune functions can release a myriad of cytokines in re-
sponse to inflammatory challenge or damage. Here, we
measured the release of 38 different factors, which were
comprised of cytokines, chemokines, growth factors and
soluble forms of receptors/adhesion molecules (seeTable 1).
In total, 13 of these were secreted, with most only after ac-
tivation by IL-1β or TNFα. Interestingly, we observed the
selective secretion of two CCL-class chemokines, MCP-1
(CCL2) and RANTES (CCL5), but no secretion of Eotaxin
(CCL11), MIP-1α (CCL3) or MIP1β (CCL4). These are,
however, sufficient to target a broad spectrum of immune-
cell subsets expressing CCR1, CCR2, CCR3 and CCR5.
Fractalkine (CX3CL1), the only known CX3CL chemo-
kine, was not secreted by the endothelial cells under basal
or activated conditions.
The CXCL chemokines (in our panel) released by the
hCMVECs were IL-8 (CXCL-8) and IP-10 (CXCL10),
whereas there was no secretion of either MIG (CXCL9)
or I-TAC (CXCL11). IL-8 is a potent chemoattractant of
neutrophils, which signals through the CXCR1 and
CXCR2 receptors, IP-10 signals through CXCR3, which
is expressed by subsets of T cells and monocytes/macro-
phages. Of particular importance to note was that the
secretion of IP-10, GCSF and GMCSF, were almost ex-
clusively induced by IL-1β, whereas the effects of TNFα
were negligible in comparison. The increased GCSF and
GMCSF maybe associated with creation of an environ-
ment within the CNS to support monocyte/macrophage
differentiation post extravasation. The endothelial cells
secrete an abundance of MCP-1 following activation,
which is a potent chemokine for monocyte/macrophage
subsets. In this study, TNFα increased the secretion of
IL-8 and RANTES to a much greater extent than that
induced by IL-1β. These differences suggest that the
leukocyte recruitment signals released by the brain
endothelial cells are considerably different between
TNFα and IL1β responses.
Truncated versions of certain receptors and adhesion
molecules can be liberated (cleaved or secreted) from
the cell surface and consequently detected in the condi-
tioned media. Here we measured the soluble forms of
the IL-1 receptors, TNF receptors and ICAM-1 and
VCAM-1. Soluble IL-1 receptors were not detected
under any conditions; however, soluble TNFα receptors
(both TNFRI and TNFRII) were detected. Interestingly,
the amount was greater following IL-1β treatment, ra-
ther than TNFα treatment. The relevance of this novel
finding is unclear but may relate to the desensitisation of
the inflammatory environment to restrict TNFα signaling.It is very interesting to note that TNFα appears to in-
duce a much greater level of ICAM-1 and VCAM-1 on
the surface of the endothelial cells, in comparison to IL-
1β. This could be due to the fact that the level of soluble
ICAM-1 and VCAM-1 present in the culture media was
greater following IL-1β activation. This demonstrates that
more ICAM-1 and VCAM-1 are cleaved during the IL-1β
response (compare the data in Figs. 3 and 6). These adhe-
sion molecules are the interacting partners of CD11 family
members (e.g. LFA-1) and CD49d (VLA-4), respectively,
which are broadly expressed by a range of leukocyte sub-
sets. This data series nicely provides the basis to conduct
adhesion/diapedesis experiments, which will be the sub-
ject of a future study. At this stage, it is exciting to hy-
pothesise that TNFα and IL-1β differentially regulate
tethering/attachment of different leukocyte subsets to the
apical surface of the brain endothelium.
As well as being a comprehensive investigation of ad-
hesion molecules important in the wider context of
endothelial biology, we reveal expression of a number of
adhesion molecules by hCMVEC not described previ-
ously for human brain endothelial cells. These include
CD138, CD141, CD147, CD325 and CD50. This advances
our understanding of their phenotype and adhesion-
molecule expression profile, all of which are molecules
important in endothelial functional biology.
A very important area clinically is the influence of
neuroinflammatory events on vascular barrier function.
Dysfunction or breakdown of the brain vascular integrity
is a well-documented event in diseases such as relapsing
remitting multiple sclerosis or in ischemic stroke pa-
tients, which can lead to vascular haemorrhage in some
stroke patients. Surprisingly, there is a lack of studies
comparing the effect of IL-1β and TNFα on barrier func-
tion using human brain endothelial cells (primary or cell
line-derived) and advanced autonomous technologies
such as ECIS. We therefore used ECIS-Ztheta system to
monitor the effect of TNFα and IL1β on barrier function
in a label-free temporal manner. Of specific importance
for us was to determine whether there were any differ-
ences between the cytokine responses and to monitor
the changes in barrier resistance either acutely (first few
hours—24 h) or chronically over days. There was a small
acute reduction in the endothelial barrier resistance in
the first few hours with higher concentrations of TNFα
(above 500 pg/mL) and IL-1β. This response was small,
reflecting approximately 10–15 % difference in norm re-
sistance. Reduced TEER over this period has been re-
ported by others [32, 33]. After this acute period, the
barrier resistance of the HCMVECs increased in a cyto-
kine, concentration and time-dependant manner. This
strengthening of the barrier occurs over a period, which
is (surprisingly) omitted in other ECIS studies [32, 33].
The magnitude of the increase in barrier resistance is
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suggests that the brain endothelial cells are innately pro-
grammed to recognise elevated TNFα as a more danger-
ous signal than IL-1β and respond accordingly in terms
of strengthening its integrity. This may also be the in-
nate response to protect against any danger signals that
may lead to neutrophil activation and invasion, which in
terms of the brain vasculature, can be devastating. Our
barrier resistance (ECIS) data for the hCMVECs highlight
the importance of conducting acute and longer term ana-
lysis of barrier function, which we have achieved in a real-
time autonomous manner using ECIS ZΘ. It is clear that
this is an area which requires considerably more research
to be conducted to understand the pathways leading to
barrier protection.
This current study highlights the fact that these two
potent inflammatory mediators induce different inflam-
matory responses from brain endothelial cells. This was
originally suggested from the xCELLigence data, which
measures the net changes in cellular focal adhesion. This
therefore indicates that the brain endothelial cells are in-
nately programmed to respond to different insults in
specific ways. Therefore in vivo, certain diseases, infec-
tions or tissue injury may cause elevated levels of IL-1β,
which may trigger different pathways and cytokine net-
works in the brain endothelium in comparison to con-
ditions where TNFα is predominantly elevated (e.g.
bacterial infection and autoimmune diseases).
Future considerations
The data obtained in this study will be invaluable for in-
vestigating the dynamics of leukocyte attachment under
different inflamed conditions and whether IL-1β induces
recruitment of different subsets of immune cells in com-
parison to TNFα. The xCELLigence technology provides a
cutting-edge tool to investigate the real-time temporal ef-
fects of activation of brain endothelial cells. In addition,
the temporal sensitivity of ECIS for investigating cytokine
changes in barrier function is incredibly powerful. This is
clearly a complex area in the field of neuroinflammation,
where there is still much to be discovered in terms of the
endothelial responses and roles in disease. This will be ap-
plied to a range of activation signals and for conducting
poly-pharmacological (multiple cytokines) analysis of how
brain endothelial cells are regulated under more complex
inflamed conditions.
Additional files
Additional file 1: Figure S1. Gating strategy for the determination of
live (P1) and dead gates (P2) for the cell-surface analysis of endothelial
adhesion molecules. The live-cell exclusion dye 7AAD was used to
determine the live-gate P1. 7AAD+ cells (detected in FL3) represent
membrane-compromised or dead cells (P2). Typically, 7AAD+ cells werenot present in P1. This gating strategy was conducted and applied in all
flow-experiments.
Additional file 2: Figure S2. Brain endothelial cytokine-secretion profile
following treatment with the PKC agonist PMA. PMA suppressed basal
production of VEGF, but the range of cytokines secreted following
activation of PKC pathways was similar to that of IL-1β and TNFα. PMA
(10 nM) treatment did not induce secretion of IL-1β and TNFα by the
endothelial cells.
Additional file 3: Figure S3. Flow-cytometry analysis of additional
endothelial cell-surface molecules. The hCMVEC line expressed CD105,
CD304 and CD141 basally, whereas basal expression of CD150 and DLL
were negligible or undetected. None of these were substantially affected
by IL-1β or TNFα treatment.
Additional file 4: Figure S4. Expression of endothelial-specific
tight-junction and adherens proteins. Immunocytochemical analysis of
the distribution of VE-cadherin (CD144) and Zonula Occludin-1 (ZO-1)
by the brain endothelial cells confirms the correct localisation of
these two critically important endothelial-specific junctional proteins.
The white arrows point to the location of the tight-junction
complexes formed between two opposing endothelial cells. Nuclei
and counter stained with Hoechst (blue).
Additional file 5: Figure S5. Direct comparison of IL-1β and TNFα on
endothelial barrier resistance measured by EICS-Ztheta. Comparisons are
shown for 50 pg/mL, 500 pg/mL, 5 ng/mL, and 50 ng/mL. The colour
coding is shown in the respective panel. In all cases, the control response
is the orange curve. Data show the normalised resistance, which was
measured at 4000 Hz for barrier function.
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